OmocianineAlternative Names: omocyanine; SF-64
Latest Information Update: 21 Mar 2011
At a glance
- Originator Bayer Schering Pharma; Fuji Photo Film
- Developer Bayer HealthCare Pharmaceuticals; Imaging Diagnostic Systems; Royal Philips Electronics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Feb 2011 No development reported - Phase-I for Breast cancer in Netherlands (IV)
- 28 Feb 2011 No development reported - Phase-I for Breast cancer in Germany (IV)
- 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG